Rigel Pharmaceuticals, Inc.  

(Public, NASDAQ:RIGL)   Watch this stock  
Find more results for RIGL
+0.09 (3.72%)
Jan 13 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.42 - 2.56
52 week 1.88 - 4.38
Open 2.44
Vol / Avg. 444,254.00/600,901.00
Mkt cap 257.57M
P/E     -
Div/yield     -
EPS -0.72
Shares 98.94M
Beta 1.38
Inst. own 95%
Mar 6, 2017
Q4 2016 Rigel Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Nov 16, 2016
Rigel Pharmaceuticals Inc at Jefferies Healthcare Conference
Nov 1, 2016
Q3 2016 Rigel Pharmaceuticals Inc Earnings Call
Nov 1, 2016
Q3 2016 Rigel Pharmaceuticals Inc Earnings Release
Oct 20, 2016
Rigel Pharmaceuticals Inc Announces Results from the Second FIT Phase 3 Study and the Long-Term Open-Label Extension Study for Fostamatinib in ITP Corporate Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -601.84% -178.11%
Operating margin -604.76% -179.07%
EBITD margin - -174.09%
Return on average assets -96.58% -36.00%
Return on average equity -129.98% -46.86%
Employees 126 -
CDP Score - -


1180 Veterans Blvd
United States - Map
+1-650-6241100 (Phone)
+1-650-6241101 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Rigel Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of targeted drugs in the therapeutic areas of immunology, oncology and immuno-oncology. The Company's clinical programs include fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which is in Phase III clinical trials for immune thrombocytopenic purpura (ITP); a Phase II clinical trial for autoimmune hemolytic anemia (AIHA), and a Phase II clinical trial for IgA nephropathy (IgAN). It has approximately two oncology product candidates in Phase I development. The Company is also engaged in conducting research in the disease areas of inflammation/immunology, and muscle wasting/muscle endurance, among others. Its product pipeline includes R348, which is a topical ophthalmic Janus kinase (JAK)/SYK inhibitor. The R348 product candidate is in Phase II clinical trials for the treatment of dry eye in patients with ocular graft-versus-host disease (GvHD).

Officers and directors

Raul R Rodriguez President, Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Ryan D. Maynard Chief Financial Officer and Executive Vice President
Age: 45
Bio & Compensation  - Reuters
Dolly A. Vance Executive Vice President, Corporate Affairs, General Counsel and Corporate Secretary
Age: 50
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Eldon C. Mayer III Executive Vice President, Chief Commercial Officer
Bio & Compensation  - Reuters
Anne-Marie Duliege M.D. Chief Marketing Officer
Age: 54
Bio & Compensation  - Reuters
Keith A. Katkin Director
Age: 43
Bio & Compensation  - Reuters
Bradford S. Goodwin Independent Director
Age: 60
Bio & Compensation  - Reuters
Gary A. Lyons Independent Director
Age: 56
Bio & Compensation  - Reuters
Walter H. Moos Ph.D. Independent Director
Age: 60
Bio & Compensation  - Reuters
Peter S. Ringrose Ph.D. Independent Director
Age: 70
Bio & Compensation  - Reuters